Lymphoma

As targeted therapies and novel treatments emerge, allogeneic hematopoietic cell transplantation has taken a backseat to immunotherapy in the treatment of lymphoma.

Overall survival was lower for patients with early-stage cutaneous T-cell lymphoma who had low-level blood involvement, according to a study.

The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat certain adults or children with acute lymphoblastic leukemia or lymphoblastic lymphoma.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.

Patients with cancer have elevated risk for atrial fibrillation development, although the degree varies by cancer type, researchers reported in JACC: CardioOncology.

The FDA granted breakthrough therapy designation to orelabrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma, according to a manufacturer-issued press release.

Patients with relapsed or refractory large B-cell lymphoma who received second-line axicabtagene ciloleucel achieved significantly longer EFS than those who received standard of care, according to data released by the agent’s manufacturer.

Fixed-duration first-line treatment with ibrutinib plus venetoclax induced deep, durable responses among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to results of the phase 2 CAPTIVATE study.

Zanubrutinib induced a superior overall response rate compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to study results.

Lisocabtagene maraleucel extended EFS and PFS compared with high-dose chemotherapy and hematopoietic stem cell transplant for relapsed or refractory large B-cell lymphoma, according to topline data released by the agent’s manufacturer.